Response to pneumococcal vaccination in children with nephrotic syndrome

J. C. Wilkes, J. D. Nelson, H. G. Worthen, M. Morris, R. J. Hogg

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Serologic responses to a 14-valent pneumococcal vaccine were measured in 20 children with steroid-responsive idiopathic nephrotic syndrome. All patients were free of proteinuria and receiving either daily (five patients) or alternate-day (15 patients) prednisone in a dosage of 1-2 mg/kg/day at the time of vaccination. Patients on alternate-day steroids received the vaccine on a day prednisone was not given. The mean fold rise in antibody titer was found to be normal in these children when antibody levels measured 3-6 wk postvaccination were compared to prevaccination levels. This serologic response has correlated well with a 3-yr follow-up of the patients, none of whom has developed peritonitis secondary to any pneumococcal types in the vaccine. Also described are three patients who developed pneumococcal peritonitis during this period despite prior vaccination; in two of these patients, the pneumococcal type was not included in the vaccine (types 6b and 10a) and in one patient the organism was not typed. It is concluded that in children with nephrotic syndrome pneumococcal vaccination confers good protection against types included in the vaccine despite the concomitant administration of steroids. However, the patients who developed peritonitis secondary to other pneumococcal types remind us that pneumococcus must still be considered as an etiologic agent for peritonitis in nephrotic children who have been vaccinated.

Original languageEnglish (US)
Pages (from-to)43-46
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume2
Issue number1
StatePublished - 1982

Fingerprint

Nephrotic Syndrome
Vaccination
Peritonitis
Pneumococcal Vaccines
Vaccines
Steroids
Prednisone
Antibodies
Streptococcus pneumoniae
Proteinuria

ASJC Scopus subject areas

  • Nephrology

Cite this

Wilkes, J. C., Nelson, J. D., Worthen, H. G., Morris, M., & Hogg, R. J. (1982). Response to pneumococcal vaccination in children with nephrotic syndrome. American Journal of Kidney Diseases, 2(1), 43-46.

Response to pneumococcal vaccination in children with nephrotic syndrome. / Wilkes, J. C.; Nelson, J. D.; Worthen, H. G.; Morris, M.; Hogg, R. J.

In: American Journal of Kidney Diseases, Vol. 2, No. 1, 1982, p. 43-46.

Research output: Contribution to journalArticle

Wilkes, JC, Nelson, JD, Worthen, HG, Morris, M & Hogg, RJ 1982, 'Response to pneumococcal vaccination in children with nephrotic syndrome', American Journal of Kidney Diseases, vol. 2, no. 1, pp. 43-46.
Wilkes, J. C. ; Nelson, J. D. ; Worthen, H. G. ; Morris, M. ; Hogg, R. J. / Response to pneumococcal vaccination in children with nephrotic syndrome. In: American Journal of Kidney Diseases. 1982 ; Vol. 2, No. 1. pp. 43-46.
@article{c6d789cec8a14875bdcaa636317d8ebf,
title = "Response to pneumococcal vaccination in children with nephrotic syndrome",
abstract = "Serologic responses to a 14-valent pneumococcal vaccine were measured in 20 children with steroid-responsive idiopathic nephrotic syndrome. All patients were free of proteinuria and receiving either daily (five patients) or alternate-day (15 patients) prednisone in a dosage of 1-2 mg/kg/day at the time of vaccination. Patients on alternate-day steroids received the vaccine on a day prednisone was not given. The mean fold rise in antibody titer was found to be normal in these children when antibody levels measured 3-6 wk postvaccination were compared to prevaccination levels. This serologic response has correlated well with a 3-yr follow-up of the patients, none of whom has developed peritonitis secondary to any pneumococcal types in the vaccine. Also described are three patients who developed pneumococcal peritonitis during this period despite prior vaccination; in two of these patients, the pneumococcal type was not included in the vaccine (types 6b and 10a) and in one patient the organism was not typed. It is concluded that in children with nephrotic syndrome pneumococcal vaccination confers good protection against types included in the vaccine despite the concomitant administration of steroids. However, the patients who developed peritonitis secondary to other pneumococcal types remind us that pneumococcus must still be considered as an etiologic agent for peritonitis in nephrotic children who have been vaccinated.",
author = "Wilkes, {J. C.} and Nelson, {J. D.} and Worthen, {H. G.} and M. Morris and Hogg, {R. J.}",
year = "1982",
language = "English (US)",
volume = "2",
pages = "43--46",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Response to pneumococcal vaccination in children with nephrotic syndrome

AU - Wilkes, J. C.

AU - Nelson, J. D.

AU - Worthen, H. G.

AU - Morris, M.

AU - Hogg, R. J.

PY - 1982

Y1 - 1982

N2 - Serologic responses to a 14-valent pneumococcal vaccine were measured in 20 children with steroid-responsive idiopathic nephrotic syndrome. All patients were free of proteinuria and receiving either daily (five patients) or alternate-day (15 patients) prednisone in a dosage of 1-2 mg/kg/day at the time of vaccination. Patients on alternate-day steroids received the vaccine on a day prednisone was not given. The mean fold rise in antibody titer was found to be normal in these children when antibody levels measured 3-6 wk postvaccination were compared to prevaccination levels. This serologic response has correlated well with a 3-yr follow-up of the patients, none of whom has developed peritonitis secondary to any pneumococcal types in the vaccine. Also described are three patients who developed pneumococcal peritonitis during this period despite prior vaccination; in two of these patients, the pneumococcal type was not included in the vaccine (types 6b and 10a) and in one patient the organism was not typed. It is concluded that in children with nephrotic syndrome pneumococcal vaccination confers good protection against types included in the vaccine despite the concomitant administration of steroids. However, the patients who developed peritonitis secondary to other pneumococcal types remind us that pneumococcus must still be considered as an etiologic agent for peritonitis in nephrotic children who have been vaccinated.

AB - Serologic responses to a 14-valent pneumococcal vaccine were measured in 20 children with steroid-responsive idiopathic nephrotic syndrome. All patients were free of proteinuria and receiving either daily (five patients) or alternate-day (15 patients) prednisone in a dosage of 1-2 mg/kg/day at the time of vaccination. Patients on alternate-day steroids received the vaccine on a day prednisone was not given. The mean fold rise in antibody titer was found to be normal in these children when antibody levels measured 3-6 wk postvaccination were compared to prevaccination levels. This serologic response has correlated well with a 3-yr follow-up of the patients, none of whom has developed peritonitis secondary to any pneumococcal types in the vaccine. Also described are three patients who developed pneumococcal peritonitis during this period despite prior vaccination; in two of these patients, the pneumococcal type was not included in the vaccine (types 6b and 10a) and in one patient the organism was not typed. It is concluded that in children with nephrotic syndrome pneumococcal vaccination confers good protection against types included in the vaccine despite the concomitant administration of steroids. However, the patients who developed peritonitis secondary to other pneumococcal types remind us that pneumococcus must still be considered as an etiologic agent for peritonitis in nephrotic children who have been vaccinated.

UR - http://www.scopus.com/inward/record.url?scp=0020363507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020363507&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 43

EP - 46

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -